Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1403-1412

  Branco, Jaime C ^a,d   Cherin, Patrick ^b   Montagne, Agnes ^c   Bouroubi, Athmane ^c  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d Multinational Coordinator Study Group   (Portugal)

Author keywords

Fibromyalgia; Longterm; Milnacipran; Pain; Serotonin norepinephrine reuptake inhibitor

Indexed keywords

MILNACIPRAN; PLACEBO;

ADULT; AGED; ANGIONEUROTIC EDEMA; AORTA DISSECTION; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; EVENING DOSAGE; FATIGUE; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; GASTRITIS; HEART FAILURE; HUMAN; HYPERHIDROSIS; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PATIENT GLOBAL IMPRESSION OF CHANGE SCORE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA HOLE; SCORING SYSTEM; SIDE EFFECT; SLEEP; TACHYCARDIA; TREATMENT RESPONSE; VERTIGO; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FIBROMYALGIA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959997862     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101025     Document Type: Article

References (46)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
2. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005;32 Suppl 75:6-21. (Pubitemid 41113954)
3. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008;62:115-26. (Pubitemid 350294025)
4. Schochat T, Croft P, Raspe H. The epidemiology of fibromyalgia. Workshop of the Standing Committee on Epidemiology European League Against Rheumatism (EULAR), Bad Säckingen, 19-21 November 1992. Br J Rheumatol 1994;33:783-6. (Pubitemid 24249193)
5. Bannwarth B, Blotman F, Roue-Le Lay K, Caubere JP, Andre E, Taieb C. Fibromyalgia syndrome in the general population of France: a prevalence study. Joint Bone Spine 2009;76:184-7.
6. Mas AJ, Carmona L, Valverde M, Ribas B, for the EPISER Study Group. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol 2008;26:519-26.
7. Coster L, Kendall S, Gerdle B, Henriksson C, Henriksson KG, Bengtsson A. Chronic widespread musculoskeletal pain - a comparison of those who meet criteria for fibromyalgia and those who do not. Eur J Pain 2008;12:600-10. (Pubitemid 351618415)
8. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005;23:819-28.
9. Lindell L, Bergman S, Petersson IF, Jacobsson LT, Herrstrom P. Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care 2000;18:149-53.
10. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39:448-53.
11. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
12. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-10.
13. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007;146:726-34. (Pubitemid 351640000)
14. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41. (Pubitemid 351498437)
15. Jones CK, Eastwood BJ, Need AB, Shannon HE. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 2006;51:1172-80. (Pubitemid 44715970)
16. Obata H, Saito S, Koizuka S, Nishikawa K, Goto F. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005;100:1406-10. (Pubitemid 40577395)
17. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6.
18. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63:7-8. (Pubitemid 34113479)
19. Stahl SM. Neurotransmission of cognition, part 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003;64:4-5. (Pubitemid 36182221)
20. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2. (Pubitemid 38117171)
21. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl -aminocarbonyl-2-aminomethyl -cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-9.
22. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002;17 Suppl 1:S25-35.
23. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85. (Pubitemid 41429029)
24. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for the treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial [published correction appears in J Rheumatol 2009;36:661]. J Rheumatol 2009;36:398-409.
25. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published correction appears in Clin Ther 2009;31:446]. Clin Ther 2008;11:1988-2004.
26. Branco JC, Zachrisson O, Perrot S, Mainguy Y, on behalf of the Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9.
27. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy, 6-month extension study. Pain Med 2010;11:180-94. Epub 2009 Dec 9.
28. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33. (Pubitemid 29001829)
29. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
30. European Agency for the Evaluation of Medicinal Products. CPMP/ICH. Note for guidance on good clinical practice. ICH E6 guidance step 5: CPMP/ICH/135/95. London: EMEA. [Internet. Accessed February 9, 2011.] Available from: http://www.fnclcc.fr/doc/pdf/lois/BPC-ICHE6.pdf
31. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
32. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med 1994;23:129-38.
33. Ware JE, Kosinski M, Dewey JE. How to score Version 2 of the SF-36 Health Survey (Standard and Acute forms). Lincoln, RI: QualityMetric Inc.; 2000.
34. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
35. Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 1994;16:93-104. (Pubitemid 24051080)
36. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory (Form Y). Self-evaluation questionnaire. Palo Alto: Consulting Psychologists Press; 1983.
37. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005;53:519-27. (Pubitemid 41278916)
38. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009;36:1304-11.
39. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100. (Pubitemid 18045797)
40. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21. (Pubitemid 351147828)
41. Farrar JT, Young JP, Lamoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58. (Pubitemid 33016608)
42. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19. (Pubitemid 40038441)
43. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2. (Pubitemid 38117171)
44. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
45. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44.
46. Arnold LM, Russell IJ, Diri EW, Duan, WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805.